The subscription period in Alligator Bioscience s rights issue commences today
News provided by
Share this article
Share this article
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, NEW ZEALAND, SOUTH AFRICA, JAPAN, AUSTRALIA, SOUTH KOREA, HONG KONG, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
STOCKHOLM, Jan. 11, 2021 /PRNewswire/
Today is the first day of the subscription period in Alligator Bioscience AB (publ) s ( Alligator or the Company ) rights issue of shares which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the Annual General Meeting on May 5, 2020 (the Rights Issue ). The general public also has the opportunity to subscribe for shares in the Rights Issue.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
STOCKHOLM, Dec. 30, 2020 /PRNewswire/ T
he Board of Directors of Alligator Bioscience AB (publ) ( Alligator or the Company ) has, in connection with the rights issue of shares which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the Annual General Meeting on May 5, 2020 (the Rights Issue ), prepared a prospectus (the Prospectus ) that today has been approved and registered by the Swedish Financial Supervisory Authority.
To ensure continued successful development in accordance with the Company s business plan and strategy, the Board of Directors of Alligator has resolved to carry out the Rights Issue of approximately SEK 86 million before issue costs. The expected net proceeds from the Rights Issue will be used to initiate and conduct Phase II studies for mitazalimab and to complete phase I study and initiate preparatory work on Phase II s
Alligator Bioscience recruits new Chief Medical Officer
LUND, Sweden, Dec. 29, 2020 /PRNewswire/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. She most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen.
Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She will report to Head of R&D, EVP Malin Carlsson, and be part of the management team. I am very pleased with the successful recruitment of Christina Reimer to Alligator. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to Phase II and another produc
Share this article
LUND, Sweden, Dec. 28, 2020 /PRNewswire/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial Authorization) application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab.
The upcoming Phase II study OPTIMIZE-1 is an open-label, multi-center study assessing the clinical efficacy of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with metastatic pancreatic cancer. The OPTIMIZE-1 study will be performed at several clinics in Europe and encompass up to a total of 66 patients. Inclusion of the first patient is planned during the first half of 2021 and will begin with a run-in period to determine the best dose for the combination with chemotherapy.